Pfizer (PFE) Income from Continuing Operations (2009 - 2026)

Pfizer has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 2709000000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 8.91% year-over-year to 2709000000.0; the TTM figure through Mar 2026 stood at 7522000000.0 (down 29.13% YoY), while the FY2025 annual figure was 7786000000.0, down 3.29% from the prior year.
• Income from Continuing Operations improved to 2709000000.0 in Q1 2026, from 1640000000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for PFE reached as high as 9877000000.0 in Q3 2022 and fell as low as 3349000000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 2974000000.0 (2025), against an average of 3112933333.33.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 127.62% — and 2025, when it soared 9264.52%.
• A 5-year view of Income from Continuing Operations shows it stood at 8645000000.0 in 2022, then tumbled by 138.74% to 3349000000.0 in 2023, then surged by 233.8% to 4481000000.0 in 2024, then slumped by 136.6% to 1640000000.0 in 2025, then surged by 265.18% to 2709000000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 2709000000.0, 1640000000.0, and 3550000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.